Skip to main content
Premium Trial:

Request an Annual Quote

HTG Molecular Diagnostics to Raise $10M in Public Offering

NEW YORK – HTG Molecular Diagnostics said on Wednesday that it has priced a public offering that is expected to raise approximately $10 million in gross proceeds.

The company is offering 1,290,322 shares of its common stock, Series A-1 warrants to purchase up to 1,290,322 shares of its common stock, and Series A-2 warrants to purchase 1,290,322 shares of its common stock at a public offering price of $7.75 per share and accompanying warrants. The Series A-1 and A-2 warrants will each have an exercise price of $7.50 per share and will be exercisable immediately upon issuance. While the Series A-1 warrants will expire five years from the date of issuance, the Series A-2 warrants will expire 24 months from that date.

The offering is expected to close on or about Dec. 23, subject to customary closing conditions. H.C. Wainwright is acting as the exclusive placement agent for the offering.

Tucson, Arizona-based HTG Molecular plans to use the net proceeds from the offering for general corporate purposes including research and development, clinical trials, capital expenditures, and working capital.

Earlier this week, the company had announced a 1-for-12 reverse stock split of its outstanding common stock.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.